Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical firm, will be presenting at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 11:15 a.m. ET. CEO James Porter, Ph.D., will lead the presentation, highlighting the company's focus on precisely targeted therapies for cancer.

The event will be accessible via a live webcast on the company's investor website and archived for 30 days. Nuvalent specializes in developing innovative small molecules aimed at overcoming therapeutic limitations in patients with ROS1-positive and ALK-positive non-small cell lung cancer.

CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 40^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 11:15 a.m. ET. 

A live webcast will be available in the investor section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent

Nuvalent, Inc. (Nasdaq: NUVL) is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), along with multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter (@nuvalent) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-present-at-the-40th-annual-jp-morgan-healthcare-conference-301453060.html

SOURCE Nuvalent, Inc.

FAQ

What is Nuvalent, Inc. focused on?

Nuvalent, Inc. specializes in creating precisely targeted therapies for cancer, aiming to address limitations of existing treatments.

When will Nuvalent present at the J.P. Morgan Healthcare Conference?

Nuvalent will present on January 12, 2022, at 11:15 a.m. ET.

Who will present for Nuvalent at the conference?

CEO James Porter, Ph.D., will lead the presentation at the conference.

Where can I watch the Nuvalent presentation?

The presentation will be available as a live webcast on Nuvalent's investor website.

What is the stock symbol for Nuvalent?

The stock symbol for Nuvalent is NUVL.

How long will the webcast of the Nuvalent presentation be available?

The webcast will be archived for 30 days following the presentation.